EGFR binding + D-K6L9 lytic peptide EGFR binding + Newly designed lytic peptideYHWYGYTPQNVIGGGLKLLKKLLKKLLKLL-NH2 YHWYGYTPQNVIGGG KLLLKLLKKLLKLLKKK
A B[θ
] (d
eg c
m2 d
mol-
1)
Wave length (nm)
C D
Fig. S1. (A)-(D) Kohno et al.
PC SUVs
PC/PS SUVs
EGFR-D-K6L9 peptide EGFR-lytic peptide
[θ]
(deg c
m2 d
mol-
1)
Wave length (nm)
PC SUVs
PC/PS SUVs
0
20
40
60
80
100
120
0 5 10 15
0
20
40
60
80
100
120
0 5 10 15
0
20
40
60
80
100
120
0 2.5 5 7.5 10
0
20
40
60
80
100
120
0 2.5 5 7.5 10
Cel
l via
bilit
y (%
con
trol
)C
ell v
iabi
lity
(% c
ontr
ol)
H322MRC-5
Fig. S2. (A)-(B) Kohno et al.
Peptide (M)Peptide (M)
A
B
Peptide (M)Peptide (M)
BT-20 HC
● EGFR-D-K6L9○ D-K6L9
● EGFR-lytic○ D-K6L9
A
27M-chimeric peptide
13M-chimeric peptide
24M-lytic peptide
12M-lytic peptide
Start injection
Stop injection
Time (s)
Res
pons
e
BH322
0.1mg/ml
0.05mg/ml
0.025mg/ml
MRC-5
CH322
Res
pons
e
0.1mg/ml
0.05mg/ml
0.025mg/ml
Res
pons
e
Time (s) Time (s)
Time (s)Time (s)
Res
pons
e
Res
pons
e
H322
MRC-5
Fig. S3. (A)-(C) Kohno et al.
0.1mg/ml
0.05mg/ml0.025mg/ml
0.0
0.2
0.4
0.6
0.8
1.0
MRC- 5 H322 BT- 20
rela
tive
KD
D
Fig. S3. (D) Kohno et al.
Lytic-TAMRA
50m
50m
50m
0 min 2 min 5 min 10 min 20 min
Calcein-green
TAMRA-red
DIC
Fig. S4. Kohno et al.
Recommended
